ORIGINAL RESEARCH
Published on 15 Aug 2025
Post marketing safety assessment of the novel postpartum depression drug, Zuranolone: evidence from real-world pharmacovigilance analysis based on the FDA adverse event reporting system
doi 10.3389/fpsyt.2025.1517773
- 962 views
